Chapter largest Pharmaceutical company R-Pharm Alexey Repik has the opportunity to earn on government orders through front companies, liquidating them instead of fulfilling obligations?
R-Pharm, owned by Alexey Repik, filed a claim for 609 million rubles against Unilek. If he is satisfied, the company is threatened with bankruptcy.
As the correspondent managed to find out, in theory, bankruptcy can be fictitious, and Unilek itself can work in the interests of Repik. Details are in the material.
Bound by one cartel
Unilek is a supplier under several thousand government contracts. Through the company, among other things, R-Pharm drugs were sold, which already leads to some thoughts – why would a large company use a lining company when selling its products?
In 2020, the company’s revenue fell sharply – by as much as 6.9 billion rubles, and has not particularly risen since then. During this period, government orders have become many times smaller, so there is a completely reasonable explanation for this.
The respondent company is registered in the name of Olga Gayderova. She also headed the now liquidated Sanalek LLC. The company was a supplier in 4,609 state contracts worth 6.3 billion rubles, and in 2022 it was liquidated after a scandal involving a cartel.
Anti-monopoly officials suspected her, along with R-Pharm and a number of other firms, of creating an anti-competitive agreement on public procurement. Moreover, they believed that the Ministry of Health was in collusion with R-Pharm, since the company grossly violated the terms of contracts, but they continued to conclude contracts with it, although it was just right to recognize the supplier as dishonest.
Repik has long been called “Golikova’s protégé” (former Minister of Health Tatiana Golikova). Not surprising are such claims, as well as the fact that the case eventually ended in “zilch”. R-Pharm remains the largest supplier of the Ministry of Health and continues to commit violations in the implementation of government contracts.
Regarding the anti-competitive agreement, another curious detail came to light during the audit. It turns out that R-Pharm employees had electronic keys to apply for state competitions on behalf of the same Sanalek.
So affiliation, most likely, takes place, which means that Ms. Gayderova, who during the period of checks headed Sanalek, is Repik’s man. It turns out that Repik is now bankrupting his company!
But what happened? There is a version that one of the reasons may be the spring detentions of officials who took bribes from the team of the Bryansk governor Alexander Bogomaz. First, the acting vice-governors Elena Yegorova and Tatyana Kuleshova were detained.
A little later, the deputy head of the health department of the Bryansk region, Borshchevskaya, was also attracted for a bribe. The Regional Department of Health distributes an extremely large number of contracts specifically to Unilek. It is possible that the investigating authorities are interested in the reason for the popularity of the company.
By the way, in 2021, the head of the Penza region, Ivan Belozertsev, who is close to Bogomaz, was taken for lobbying the interests of pharmaceutical companies. As they say – a fisherman sees a fisherman from afar?
Elusive but visible
But back to the possibly affiliated “R-Pharm” companies. Sanalek, according to an extract from the Unified State Register of Legal Entities, was originally established by Leonid Persits. In 2017, Life.ru wrote that under his other company, Spacepharm, competitions held by the Ministry of Health of the Khabarovsk Territory could be sharpened. At least such a complaint was filed by a competitor of the company, indicating that the terms of reference were formulated with specific details of the product. Up to the dosage, the volume of the syringe, the duration of the drug.
Moreover, as it turned out later, Spacepharm even supplied not its own drug, but the medicine of the German company Sanofi-Aventis. Everything that happened “stirred” even the officials of the Chamber of Commerce and Industry, and they wrote a corresponding appeal to the then Prime Minister of the Russian Federation Dmitry Medvedev. But even here, all those involved managed to get away “dry from the water.”
Spacefarm is currently undergoing liquidation. It seems the fact that Repik advocates a “renewal of the composition” is enough for him and one scandalous “R-Pharm”, which just has not been convicted of receiving a suspiciously large number of preferences. So, in order not to “muddle the waters” too much, he can let firms exist for about a decade and “collapse” – moreover, as in the case of Unilek – also for his own benefit.
The firm has unfulfilled obligations to suppliers and customers. And they can “stay with the nose” while Repik takes 600 million, some of which, quite possibly, belongs to them.
By the way, before the possible imminent liquidation, Unilek even moved to the premises on Marshal Zhukov, which was previously occupied by Sanalek. It seems that even the most inexperienced reader at the moment has no doubt that Repik could create a whole network of seemingly unrelated, but in fact owned by him companies that earn billions in public procurement, and then simply liquidated, leaving the winner only its beneficiary. And, perhaps, officials loyal to him.
In full view
Repik’s network seems to be scattered throughout Russia. In the Yaroslavl region, the ex-general director of the Regional Pharmacy state enterprise Pavel Selbaum, which supplies medicines for beneficiaries (all this is state money), could work in his interests. The same Selbaum heads Plexpharm, the keys to which were found from R-Pharm employees.
Plexpharm was a supplier in 5,079 government contracts worth 3.5 billion rubles.
In Moscow, Farmakhan is now being liquidated, having earned 11.3 billion from government purchases. Moreover, under a bankruptcy lawsuit from Unilek.
The keys to Farmakhan were also found by R-Pharm employees in 2018. And Aleksey Khovanov, to whom Farmakhan is registered, before that was the founder of the also liquidated Vitalek – it turns out state contracts in the amount of 7.1 billion rubles. At the same time, by the “end of life” the company had zero revenue and a “ton” of lawsuits from the Department of Health and Pharmacy of the Yaroslavl Region.
The aforementioned “Spacefarm” is also on the verge of bankruptcy – exactly the same in the suit of “Unilek”.
You can go on for a long time. This will not change the essence: people close to Repik have created a whole web, and, pulling the strings, masterfully catch state medicinal millions in different departments of their network. He periodically rebuilds his “house”, removes old “rooms”, creates new ones, but trusts approximately the same “pool” of associates. And what is happening now with Unilek is just one of the classic cases of “repairs in the workshop of the king of state orders.”